EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical efficacy and safety of adjuvant EGFR‐TKIs for resected stage IB lung adenocarcinoma: A real‐world study based on propensity score matching

Leilei Shen iD, Juntang Guo iD, Weidong Zhang, Lianbin Zhang, Xi Liu, Tao Wang, Tao Zhang, Chaoyang Liang, Yang Liu

Cancer Medicine · 2023

DOI: 10.1002/cam4.6443 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Leilei Shen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate School, Medical School of Chinese PLA, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Special Science and Technology Projects for university and medical institutions of Sanya city.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adjuvant therapy for stage IB non‐small cell lung cancer remains debatable. In this real‐world study, we evaluate the efficacy and safety of adjuvant epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) for resected stage IB lung adenocarcinoma.

Methods

This real‐world study recruited 249 patients diagnosed with stage IB disease after surgical resection between January 2013 and September 2021. Sixty‐six (26.5%) patients received adjuvant targeted therapy (TKIs group), and 183 (73.5%) were enrolled in the clinical observation (CO) group. Propensity scores were matched to minimize the observed confounder effects between the two groups, and 59 patient pairs were matched. The primary endpoint was disease‐free survival (DFS).

Results

In the TKI group, 38 (64.4%) patients chose to receive icotinib, 27.1% (16/59) received gefitinib, and 5 patients (8.5%) chose osimertinib. The median follow‐up time was 30.8 months (range: 7–107 months). Two (3.4%) patients in the TKI group and 10 (16.9%) in the CO group experienced disease relapse. The 3‐year DFS rates were 98.3% in the TKI group and 83.0% in the CO group (HR: 0.10; 95% CI: 0.01–0.78; p = 0.008). DFS differences were found in the entire cohort ( p = 0.005) and the matched cohort ( p = 0.024) between the two groups. Multivariate analysis showed that adjuvant EGFR‐TKIs was an independent factor for DFS (HR: 0.211; 95% CI: 0.045–0.979; p = 0.047), along with poor cell differentiation (HR: 5.256; 95% CI: 1.648–16.769; p = 0.005), and spread through air spaces (HR: 5.612; 95% CI: 1.137–27.700; p = 0.034). None of the patients discontinued EGFR‐TKIs owing to the low occurrence rate of treatment‐related serious adverse events.

Conclusion

Adjuvant EGFR‐TKIs could significantly improve DFS among patients with stage IB lung adenocarcinoma compared with CO, with a safe and tolerable profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungLung NeoplasmsProtein Kinase InhibitorsHumansFemaleMalePropensity ScoreMiddle AgedErbB ReceptorsAgedChemotherapy, AdjuvantNeoplasm StagingGefitinibRetrospective StudiesAdultTreatment OutcomeAniline CompoundsAged, 80 and overQuinazolinesAcrylamidesIndolesPyrimidinesCrown Ethers

Stichwörter der Autor:innen

EGFR-TKIsadenocarcinomaadjuvant therapydisease-free survivalsstage IB

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsEGFR protein, humanGefitinibosimertinibicotinibAniline CompoundsQuinazolinesAcrylamidesIndoles

Autor:innen und Institutionen

  • Postgraduate School, Medical School of Chinese PLA, Beijing, People's Republic of China.
  • Department of Thoracic Surgery, Chinese PLA General Hospital, Beijing, People's Republic of China.
  • Department of Thoracic Surgery, Hainan Hospital of Chinese PLA General Hospital, Sanya, People's Republic of China.
  • Department of Thoracic Surgery, The First Medical Center of Chinese PLA General Hospital, Beijing, People's Republic of China.

ORCID-Profile: Leilei Shen, Juntang Guo

Förderung

  • Special Science and Technology Projects for university and medical institutions of Sanya city

Zitieren

APA

Shen, L., Guo, J., Zhang, W., Zhang, L., Liu, X., Wang, T., Zhang, T., Liang, C., & Liu, Y. (2023). Clinical efficacy and safety of adjuvant EGFR‐TKIs for resected stage IB lung adenocarcinoma: A real‐world study based on propensity score matching. Cancer Medicine. https://doi.org/10.1002/cam4.6443

Vancouver

Shen L, Guo J, Zhang W, Zhang L, Liu X, Wang T, et al. Clinical efficacy and safety of adjuvant EGFR‐TKIs for resected stage IB lung adenocarcinoma: A real‐world study based on propensity score matching. Cancer Medicine. 2023. doi:10.1002/cam4.6443

BibTeX
@article{Shen2023,
  author = {Shen, Leilei and Guo, Juntang and Zhang, Weidong and Zhang, Lianbin and Liu, Xi and Wang, Tao and Zhang, Tao and Liang, Chaoyang and Liu, Yang},
  title = {Clinical efficacy and safety of adjuvant EGFR‐TKIs for resected stage IB lung adenocarcinoma: A real‐world study based on propensity score matching},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6443}
}
Kostenlos starten →